LibrarianMeg said:

I have been dealing with this for about 6 months now, and what I have found is that individual respo

I respect LibrarianMeg perspective but I think this oversimplifies things a bit. Re: GLP-1 therapy in patients over — the subgroup analyses show meaningful heterogeneity.

I am not saying LibrarianMeg wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.

Relevant to GLP-1 therapy in patients over — here is my latest bloodwork comparison:

Key improvements: A1C 8.4% → 5.5%, triglycerides 201 → 101 mg/dL, hsCRP 8.0 → 1.3 mg/L. All on tirzepatide for 17 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you GenomicsKate! This is incredibly helpful. Taking this to my next appointment. 🙏

Slightly tangential to GLP-1 therapy in patients but SallyK_inj reminded me — does anyone have experience combining this with metformin?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Great discussion, everyone. Just a reminder to keep things civil and evidence-based.

Thread quality is excellent — keep it up. 👍